TP005/#1564  Gog-3069: phase 2 study of alpelisib and fulvestrant for PIK3CA-mutated estrogen receptor-positive endometrioid endometrial cancers

Stéphanie Gaillard, Michael W. Sill, Jennifer Klein, Michael J. Callahan, Thomas Reid, Julia Fehniger, Janelle Sobecki, Michael Gold, Mihae Song, Robert G. Holloway, Matthew Anderson, Thomas J. Herzog, Brian M. Slomovitz, Ursula A. Matulonis
In: International Journal of Gynecological Cancer · 2024 · vol. 34 , pp. A349 · doi:10.1136/ijgc-2024-igcs.607 · W4403533395
article OA: closed CC0
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This phase 2 study investigated alpelisib and fulvestrant in patients with PIK3CA-mutated, estrogen receptor-positive endometrioid endometrial cancer.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2024) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK